Figure 4

Effects of the expression of SATB1, HER2 and HR to patients’ survival time in breast cancer by Kaplan–Meier analysis. A Overall survival for patients with positive SATB1 expression was significantly lower than that with negative expression (SATB1 positive vs SATB1 negative, p = 0.001). B Overall survival for patients with positive HER2 was significantly lower than that with negative expression (HER2 positive vs HER2 negative, p = 0.000). C SATB1/HER2 co-expression showed the worst prognosis. D Patients’ overall survival with positive HR was significantly higher than that with negative expression (HR positive vs HR negative, p = 0.000).